SOLID TUMOR, ADULT

This early-phase study tests the safety of a new drug called OK-1 (SHetA2) in about 50 adults with advanced or recurrent solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and identify side effects. Researchers will also monitor whet…

This early-phase study tests an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects, while al…

This study tests a new drug called CX-2051 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. About 160 adults will take part, and the drug may be given alone or with anot…

This early-stage study tests a new drug, ADU-1805, in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with another cancer drug (pembrolizumab). The main goals are to check safety and how the body processes the drug. Abo…

This early-phase trial tests a new treatment called VET3-TGI, a virus designed to infect and kill cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main go…

This study tests a new drug (BI-1206) combined with an approved immunotherapy (pembrolizumab) in people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the combination is safe and can help control the cancer. About 197 adults w…

This study tests a drug called patritumab deruxtecan in 30 adults with advanced solid tumors that have a rare NRG1 gene fusion. The drug targets a protein on cancer cells to stop their growth. The main goal is to see how many patients' tumors shrink or disappear.

This early-stage study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. Researchers will also look for si…

This early-stage study tests a new treatment using a patient's own immune cells, modified in a lab to recognize and attack cancer cells with a specific KRAS mutation (G12D). It is for adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not respond…

This early-phase study tests a new daily pill, TRE-515, in adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and loo…

This study tests an experimental drug called ACE-86225106 in adults with advanced solid tumors (like ovarian, breast, or prostate cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tu…

This study tests a new treatment called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced solid tumors. About 18 adults who have not responded to standard treatments will receive this personalized cell therapy. The main goal is to c…

This study tests a new drug called CRB-701 for people with advanced solid tumors that have a specific protein (nectin-4). The goal is to find a safe and effective dose and see which cancers it may help. Participants receive the drug through an IV and are monitored with scans and …

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to an existing immunotherapy (atezolizumab) can help control several advanced solid tumors, including pancreatic, lung, bladder, and triple-negative breast cancer. About 247 adults with t…

This early-phase trial tests a new drug called ATTR-01 in adults with certain solid tumors that have not responded to standard treatments. ATTR-01 is a modified cold virus designed to infect and multiply only in cancer cells, delivering an immune-boosting therapy to help the body…

This study tests an experimental drug, HMPL-453, in people with advanced bile duct cancer that has a specific change in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug as a pill for 14 days, then a 7-day break…

This study tests two drugs, neratinib and valproate, together in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest and most effective dose, and then see how well the combination works against cancers with a RAS m…

This study is testing an experimental drug called VT3989, taken as a pill once a day, for people with advanced solid tumors or mesothelioma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors or slow cancer gro…

This study tests whether the drug nivolumab can be safely given after a half-matched bone marrow transplant to help prevent sarcoma from returning. It includes children and young adults (ages 1 to 50) with high-risk, recurrent, or hard-to-treat sarcomas. Researchers will monitor …

This study tests whether giving the immunotherapy drug TSR-042 first, followed by standard chemoradiotherapy and surgery, can shrink or eliminate advanced solid tumors that have a specific genetic feature called mismatch repair deficiency (dMMR). About 212 adults with locally adv…

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to check safety and side effects. About 33 participants will be enrolled to see if this comb…

This study tests a new drug, DB-1419, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 360 participants will take part in this early-phase tria…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study is testing whether combining two experimental drugs (AK119 and AK112) is safe and can shrink tumors in people with advanced solid tumors that have stopped responding to standard treatments. About 87 adults aged 18 to 75 will participate. The goal is to find the best do…

This early-phase study tests a new drug called BBO-10203 in about 392 adults with advanced solid tumors (like breast, lung, or colorectal cancer) that have not responded to other treatments. The drug works by blocking a key cancer growth pathway. The main goals are to find the sa…

This early-stage study tests a new drug, RLY-2608, designed to target a specific genetic mutation (PIK3CA) found in some advanced solid tumors and breast cancers. The trial will enroll about 930 adults whose cancer has not responded to other treatments. Researchers aim to find th…

This study tests whether adding a drug called ATRA (a form of vitamin A) to precise radiation therapy can prevent a drop in infection-fighting white blood cells (lymphocytes) in adults with solid tumors that have spread to a few spots. About 58 participants will receive radiation…

This early study tests a new drug called CX-801, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 121 people will take part.

This study is for adults with advanced solid tumors that have stopped responding to standard treatments. It tests an experimental drug called INV-1120, given alone or together with the immunotherapy pembrolizumab. The main goals are to find the safest dose and to watch for side e…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have lost a specif…

This study tests an experimental therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 18 adu…

This study tests an inhaled therapy called KB707 for people with advanced solid tumors that have spread to the lungs. KB707 is a modified virus designed to trigger the immune system to attack tumors. The trial involves 250 adults who have not responded to or cannot tolerate stand…

This early-stage study is testing a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with solid tumors that have returned or not responded to treatment. The main goal is to find a safe dose and check for side effects. The study is…

This early-stage trial is testing whether personalizing standard radiotherapy based on how a patient's tumor responds can be safe and effective. It includes two groups: one for extensive-stage small cell lung cancer patients receiving chemoimmunotherapy, and another for people wi…

This early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…

This early-phase trial tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway and have stopped responding to standard treatments. The study aims to find a safe dose and check for early signs of tumor s…

This early-stage study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that haven't responded to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined with chem…

This early-phase trial tests an experimental drug called IMA402 in about 145 adults with advanced solid tumors that have returned or not responded to standard treatments. IMA402 is a bispecific T-cell engager designed to direct the immune system to attack cancer cells carrying a …

This study tests a new drug called LNS8801, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 200…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. Some participants will also receive an immunotherapy drug …

This study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…

This study tests a combination of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) to see if they are safe and can control advanced solid tumors or relapsed prostate cancer. The trial has two phases: first finding the safest dose, then checkin…

This study tests a new oral drug, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The trial will first find the safest dose, then check if the drug shrinks tumors when used alone or with other ca…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have certain genetic changes. The study aims to find safe doses of KQB198 alone or with other cancer drugs, and to see if it can shrink tumors. About 100 participants will take the dru…

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study is testing a culturally tailored counseling program for Latinos with advanced cancer. The goal is to improve their quality of life and emotional well-being. About 285 adults who speak Spanish or both Spanish and English will take part. Researchers will measure changes …

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, have trouble sleeping, or are very tired. The program is delivered through telehealth (video or phone calls) and includes up to 8 sessions. Resear…

This study aims to adapt a counseling approach called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. Researchers will work with 190 participants to see if the culturally tailored program improves spiritual well-being and eases anxiety and depressio…

This study is adapting a program called CONVO for Spanish-speaking Latinx cancer patients. In the program, nurses and patients talk about the patient's personal values during routine cancer care. The goal is to make sure care aligns with what matters most to each patient.

This study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …

This study uses a special microscope called intravital microscopy (IVM) to watch blood vessels inside solid tumors in real time during surgery. Researchers want to see how these vessels work, which could help decide if a patient's tumor is likely to respond to certain treatments.…

This study collects blood samples from 1,500 adults with solid tumors, healthy volunteers, and COVID-19 donors. Researchers will use these samples to develop a device that can grow and test immune cells (T cells) outside the body. The goal is to learn how to select and expand can…

This study tests a new radioactive tracer called 64Cu-GRIP B, which attaches to a protein (granzyme B) made by immune cells. By using PET scans, doctors hope to see which tumors are responding to immunotherapy. The trial involves about 91 adults with advanced prostate, kidney, or…

This study is creating a detailed database of 651 adults with solid tumors who are starting immunotherapy. Researchers will track their health over 5 years to see how well these treatments work in everyday medical practice. The goal is to learn more about outcomes like survival a…